Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

About us

Committed to transforming the treatment of severe, chronic autoimmune diseases

From a discovery made at the Catholic University of Leuven (KUL), Imcyse located in Liège (Belgium), is a clinical-stage biopharmaceutical company pioneering the development of a new class of antigen specific immunotherapies.

With an initial focus in severe autoimmune diseases, the Company’s unique ImotopeTM technology platform has the potential to make a meaningful impact on a wide range of indications in the field of autoimmunity, as well as other diseases where the immune system natural balance and controls break down. The Imcyse approach could stop disease progression and potentially provide a cure for some of the most challenging and underserved areas of modern medicine.

Our revolutionary technology – aiming to cure

The Imcyse journey began when the founders discovered the ability of certain peptides to stimulate the immune system in a new way. After further investigation they invented new peptides, called ImotopesTM and showed these could induce a special type of T cell (cytolytic CD4+ T cell) that breaks the chain of events leading to severe autoimmune disease.

The carefully designed synthetic peptides, ImotopesTM, stimulate T cells to develop into a new phenotype which in turn can control the disease inflammatory processes and autoimmune attack. While many current therapies for autoimmune diseases trigger a general suppression of the immune system, this discovery allows the body’s own immune system to delete only the cells that drive abnormal immune attack but leave the rest of the immune system functioning normally. This stops tissue and organ damage and disease progression and can create a favorable environment for potential healing of the damaged organ.

Broad pipeline to tackle some of the most underserved areas in modern medicine

Imcyse continues to develop the technology, optimizing and advancing both the platform and each program.

With clinical-stage assets in Type 1 diabetes and Multiple sclerosis and several pre-clinical programs in large and rare disease indications we have developed a diverse pipeline. We have entered into our first strategic partnership, with Pfizer, to advance the development of ImotopesTM to treat Rheumatoid arthritis (RA). We aim to continue to develop and commercialize our products both through partnership with Pharma and others to be developed ourselves.

In 2021, Imcyse relocated to a new purpose-built premises in the Liège Science Park, to enable strong growth and the development of laboratories tailor-made to our scientific needs. The new R&D center features customized labs to advance its scientific programs and boost pipeline progress as well as the expansion of the Imotope™ platform to new indications and therapeutic areas.

Leadership Team




Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.


Investors & Partners

Imcyse has continued to develop with the support of investments from key shareholders (including Biogenosis, EQT Life Sciences, KUL, Noshaq, SFPI, Wallonie Entreprendre) as well as a number of grants and awards from the Walloon Region.

Following the successful completion of a research collaboration initiated in 2017, in 2020 Imcyse and Pfizer entered into a research and collaboration license agreement covering the development of the ImotopeTM technology for the treatment of Rheumatoid Arthritis. With this licensing agreement and then acquisition of the IP from KUL, Pfizer and LSRP also joined as shareholders.

In March 2020, Imcyse became a proud member of INNODIA, a global network of academic institutions, industrial partners, patient organizations and a small-sized enterprise bringing together their knowledge and experience to fight Type 1 Diabetes (T1D), Imcyse’s lead indication. This private-public partnership offers Imcyse greater access to T1D patients as well as to a platform of scientific exchange and technical approaches that will help the Company as it further refines treatment with ImotopesTM for patients with early T1D.  

©imcyse 2023